Coagulation factor XIII serves as protein disulfide isomerase
Judith Lahav1*; Eli Karniel2*; Zsuzsa Bagoly3; Vera Sheptovitsky1; Rima Dardik4; Aida Inbal5
1Hemostasis Laboratory, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Internal Medicine Department B, Meir Hospital, Kfar Saba, Israel; 3Clinical Research Center, Haemostasis, Thrombosis and Vascular Biology Research Group of the Hungarian Academy of Sciences, University of Debrecen, Medical & Health Science Center, Debrecen, Hungary; 4Thrombosis and Hemostasis Unit, Sheba Medical Center, Tel Hashomer, Israel; 5Thrombosis and Hemostasis Unit, Department of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Israel
Summary
Tissue transglutaminase was reported to act as protein disulfide isomerase (PDI). We studied whether plasma transglutaminase – coagulation factor XIII (FXIII) – has PDI activity as well. PDI activity was measured by determining the ability to renature reduced- denatured RNase (rdRNase). We found that FXIII can renature rdRNase, with efficiency comparable to commercial PDI. This PDI activity was inhibited by bacitracin. Like tissue transglutaminase, FXIII-mediated PDI activity is independent of its transglutaminase activity and is located on the A subunit. Surface-associated PDI has been previously shown to catalyse two distinct functions: transnitrosation with subsequent release of intracellular nitric oxide and disulfide bond rearrangement during platelet integrin ligation. Our results imply that FXIII-PDI activity may have a role in platelet function. Keywords
factor XIII, Transglutaminase, PDI
DOI
http://dx.doi.org/10.1160/TH08-09-0605